A Phase 1 interventional study of Mavacamten in Hypertrophic Cardiomyopathy, sponsored by LianBio LLC. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-25.
Sponsored by LianBio LLC · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 16th largest by enrollment, is the only one that started in 2021, is one of 5 in phase 1, and was the 9th registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:
University of Manchester · Sites in United Kingdom
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University
Ages 18+
By country, each count listing its studies:
MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 7 · Phase 4 4
First in 2014; this study’s year is marked. 1 started in 2021.
This study's enrollment of 45 is below the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 75 across the 21 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
LianBio LLC is the lead sponsor of 7 studies on the registry; none are open to participants now.
LianBio LLC has 2 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Mavacamten is a small-molecule allosteric inhibitor of cardiac myosin that reversibly inhibits its binding to cardiac actin, thereby relieving systolic hypercontractility and improving ventricular compliance. This is an open-label, parallel-group, single-center Phase 1 clinical study. Healthy adult Chinese subjects with different genotypes will be included and administered with a single fasted oral dose of mavacamten to evaluate its PK profile. Up to 44 subjects will be enrolled in this study.
Approximately 44 healthy adult Chinese subjects are expected to be enrolled in this study according to their genotypes into 4 cohorts.
The doses administered include: 15 mg for cohort 1; 25 mg for Cohort 2; 15 mg for Cohort 3; 15 mg for Cohort 4. Blood samples will be collected from subjects at scheduled time points for PK testing. Series of safety assessments (including but not limited to AEs, laboratory tests, vital signs, and ECGs) will be performed during the whole study at specified time points.
This study will consist of the following 5 periods:
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1: 15 mg capsules × 1 on Day 1
Drug: Mavacamten
Cohort 2: 10 mg capsules x 1 and 15 mg capsules x 1 on Day 1
Drug: Mavacamten
Cohort 3: 15 mg capsules × 1 on Day 1
Drug: Mavacamten
Cohort 4: 15 mg capsules × 1 on Day 1
Drug: Mavacamten
Single fasted oral dose of Mavacamten 15/25 mg on Day 1
Also known as: Mavacamten capsule
Area Under the Curve (AUC) (0-last), AUC(0-inf)
Determination of pharmacokinetics parameters as measured by area under curve AUC(0-last), AUC(0-inf)
Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Maximum Concentration (Cmax)
Determination of pharmacokinetics parameters as measured by maximum concentration (Cmax)
Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Time to Maximum Concentration (Tmax)
Determination of pharmacokinetics parameters as measured by time to maximum concentration (Tmax)
Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Elimination Half-life (T1⁄2)
Determination of pharmacokinetics parameters as measured by elimination half-life (T1⁄2)
Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Apparent Volume of Distribution (Vd/F)
Determination of pharmacokinetics parameters as measured by apparent volume of distribution (Vd/F)
Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Apparent Clearance (CL/F)
Determination of pharmacokinetics parameters as measured by apparent clearance (CL/F)
Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Number of Participants With Adverse Events
Safety assessments will be performed by incidence of adverse events during the whole study at specified time points
Time frame: Up to 75 days
Body Weight at Screening and EOS
Safety assessments will be performed by vital signs during the whole study at screening, Day-1, Day 3 and at the EOS Visit. A complete physical examination includes assessments of general appearance, skin, head and neck, chest, abdomen, back, spine, extremity neurological, and mental systems. Brief physical examination means chest examinations. Height (cm) and body weight (kg) will be measured at screening, and BMI (kg/m2) will be calculated. Body weight (kg) will be measured at EOS. The mean weight and the standard deviation are analysis for different cohort.
Time frame: Body weight (kg) will be measured at screening (baseline) and EOS(75 days).
Physical Examination Findings
Safety assessments will be performed by physical examination findings during the whole study at specified time points
Time frame: Up to 75 days
Heart Rate at Baseline and Day 75
Safety assessments will be performed by electrocardiogram (ECG) parameters findings during the whole study at specified time points
Time frame: Up to 75 days
Clinical Laboratory Tests Data
Safety assessments will be performed by clinical laboratory tests data(including hematology and blood chemistry, coagulation and urinalysis parameters) during the whole study at specified time points
Time frame: Up to 75 days
| Milestone | Cohort 2: Mavacamten 25 mg | Cohort 1: Mavacamten 15 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Started | 13 | 12 | 12 | 8 |
| Completed | 12 | 12 | 12 | 8 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: 1 subject withdrew from the study before administration of the imp due to pre-dose abnormal ecg | 1 | 0 | 0 | 0 |
Determination of pharmacokinetics parameters as measured by area under curve AUC(0-last), AUC(0-inf)
| h*ng/mL | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| (AUC) (0-last) | 9956 ± 35.61 | 20040 ± 50.49 | 18270 ± 21.05 | 39980 ± 23.60 |
| AUC(0-inf) | 10030 ± 35.44 | 20280 ± 52.47 | 18430 ± 21.18 | 45810 ± 25.51 |
Determination of pharmacokinetics parameters as measured by maximum concentration (Cmax)
| ng/mL | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Maximum Concentration (Cmax) | 395.4 ± 39.95 | 571.8 ± 25.69 | 485.2 ± 34.96 | 435.7 ± 35.66 |
Determination of pharmacokinetics parameters as measured by time to maximum concentration (Tmax)
| h | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Time to Maximum Concentration (Tmax) | 0.88 (0.50 to 3.00) | 1.50 (0.50 to 4.00) | 0.75 (0.50 to 3.00) | 0.63 (0.33 to 1.00) |
Determination of pharmacokinetics parameters as measured by elimination half-life (T1⁄2)
| h | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Elimination Half-life (T1⁄2) | 120.3 ± 23.44 | 143.6 ± 42.32 | 205.4 ± 22.31 | 572.0 ± 25.03 |
Determination of pharmacokinetics parameters as measured by apparent volume of distribution (Vd/F)
| mL | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Apparent Volume of Distribution (Vd/F) | 259500 ± 29.93 | 255300 ± 16.60 | 241200 ± 23.13 | 270200 ± 26.95 |
Determination of pharmacokinetics parameters as measured by apparent clearance (CL/F)
| mL/h | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Apparent Clearance (CL/F) | 1495 ± 35.44 | 1233 ± 52.47 | 814.0 ± 21.18 | 327.5 ± 25.51 |
Safety assessments will be performed by incidence of adverse events during the whole study at specified time points
| Participants | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Number of subjects with at least 1 AE | 3 | 6 | 9 | 3 |
| Number of subjects with at least 1 TEAE | 3 | 6 | 9 | 3 |
| Worst severity of TEAE(Mild) | 3 | 6 | 8 | 3 |
| Worst severity of TEAE(Moderate) | 0 | 0 | 1 | 0 |
| Worst severity of TEAE(Severe) | 0 | 0 | 0 | 0 |
| Drug-related TEAEs | 0 | 1 | 0 | 1 |
| TESAE | 0 | 0 | 0 | 0 |
| TEAE leading to study discontinuation | 0 | 0 | 0 | 0 |
| TEAE leading to death | 0 | 0 | 0 | 0 |
| AESI | 0 | 0 | 0 | 0 |
Safety assessments will be performed by vital signs during the whole study at screening, Day-1, Day 3 and at the EOS Visit. A complete physical examination includes assessments of general appearance, skin, head and neck, chest, abdomen, back, spine, extremity neurological, and mental systems. Brief physical examination means chest examinations. Height (cm) and body weight (kg) will be measured at screening, and BMI (kg/m2) will be calculated. Body weight (kg) will be measured at EOS. The mean weight and the standard deviation are analysis for different cohort.
| kg | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Change from Baseline | 0.80 ± 2.899 | 0.70 ± 1.738 | -0.36 ± 2.378 | 1.25 ± 2.184 |
| Baseline | 69.41 ± 12.699 | 62.78 ± 8.458 | 65.89 ± 11.157 | 68.26 ± 11.147 |
| Day 75 | 70.21 ± 13.088 | 63.48 ± 9.405 | 65.53 ± 10.929 | 69.51 ± 11.530 |
Safety assessments will be performed by physical examination findings during the whole study at specified time points
| participants | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Number of abnormal but not clinically significant comprehensive physical examinations in baseline | 5 | 2 | 4 | 2 |
| Number of abnormal but not clinically significant comprehensive physical examinations in Day 75 | 5 | 2 | 4 | 2 |
| The number of abnormal with clinically significant comprehensive physical examinations in Day 75 | 0 | 1 | 0 | 0 |
Safety assessments will be performed by electrocardiogram (ECG) parameters findings during the whole study at specified time points
| beats/min | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Heart Rate-Baseline | 63.3 ± 8.70 | 63.0 ± 10.44 | 63.3 ± 10.44 | 62.8 ± 9.27 |
| Heart Rate-D75 | 64.8 ± 7.12 | 66.4 ± 7.88 | 67.5 ± 5.35 | 66.8 ± 7.17 |
Safety assessments will be performed by clinical laboratory tests data(including hematology and blood chemistry, coagulation and urinalysis parameters) during the whole study at specified time points
| participants | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Blood fibrinogen increased | 0 | 0 | 1 | 1 |
| White blood cell count decreased | 0 | 1 | 0 | 1 |
| Alanine aminotransferase increased | 0 | 0 | 1 | 0 |
| Neutrophil count increased | 0 | 0 | 1 | 0 |
| Neutrophil count decreased | 0 | 0 | 0 | 1 |
| Eosinophil percentage increased | 0 | 0 | 1 | 0 |
| Eosinophil count increased | 0 | 0 | 1 | 0 |
| Urobilinogen urine increased | 0 | 0 | 0 | 1 |
| White blood cell count increased | 0 | 1 | 0 | 0 |
| Hemoglobin decreased | 0 | 0 | 0 | 1 |
Collected over The study took about 80 days to monitor the adverse event for each subject.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Mavacamten 15 mg | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Cohort 2: Mavacamten 25 mg | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Cohort 3: Mavacamten 15 mg | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| Cohort 4: Mavacamten 15 mg | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/12 | 3/12 | 3/12 | 1/8 |
| Chest painGeneral disorders | 0/12 | 2/12 | 1/12 | 0/8 |
| Blood fibrinogen increasedInvestigations | 0/12 | 2/12 | 1/12 | 0/8 |
| White blood cell count decreasedInvestigations | 0/12 | 1/12 | 0/12 | 1/8 |
| Neutrophil count decreasedInvestigations | 0/12 | 0/12 | 0/12 | 1/8 |
| Urobilinogen urine increasedInvestigations | 0/12 | 0/12 | 0/12 | 1/8 |
| Hemoglobin decreasedInvestigations | 0/12 | 0/12 | 0/12 | 1/8 |
| Oral herpesInfections and infestations | 0/12 | 0/12 | 1/12 | 0/8 |
| GastroenteritisInfections and infestations | 0/12 | 0/12 | 1/12 | 0/8 |
| AppendicitisInfections and infestations | 0/12 | 1/12 | 0/12 | 0/8 |
| Age, Continuous(years) | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg | Total |
|---|---|---|---|---|---|
| Mean | 26.8 ± 4.99 | 31.0 ± 7.12 | 28.9 ± 6.32 | 35.4 ± 4.31 | 30.1 ± 6.44 |
| Sex: Female, Male(Participants) | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg | Total |
|---|---|---|---|---|---|
| Female | 3 | 3 | 3 | 2 | 11 |
| Male | 9 | 9 | 9 | 6 | 33 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg | Total |
|---|---|---|---|---|---|
| Chinese | 12 | 12 | 12 | 8 | 44 |
| Non-Chinese | 0 | 0 | 0 | 0 | 0 |
| Han | 12 | 12 | 12 | 8 | 44 |
| Non-Han | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg | Total |
|---|---|---|---|---|---|
| China | 12 | 12 | 12 | 8 | 44 |
| Body mass index(kg/m^2) | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg | Total |
|---|---|---|---|---|---|
| Mean | 24.34 ± 2.444 | 23.82 ± 2.571 | 23.26 ± 2.434 | 23.04 ± 2.312 | 23.67 ± 2.421 |
| CYP2C19 genotype(Participants) | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg | Total |
|---|---|---|---|---|---|
| Ultra-rapid metabolizer | 0 | 0 | 0 | 0 | 0 |
| Rapid metabolizer | 1 | 1 | 0 | 0 | 2 |
| Normal metabolizer | 11 | 11 | 0 | 0 | 22 |
| Intermediate metabolizer | 0 | 0 | 12 | 0 | 12 |
| Poor metabolizer | 0 | 0 | 0 | 8 | 8 |
| Left ventricular ejection fraction(%)(%) | Cohort 1: Mavacamten 15 mg | Cohort 2: Mavacamten 25 mg | Cohort 3: Mavacamten 15 mg | Cohort 4: Mavacamten 15 mg | Total |
|---|---|---|---|---|---|
| Mean | 68.0 ± 5.03 | 66.9 ± 396 | 66.4 ± 3.99 | 64.0 ± 5.58 | 66.5 ± 4.63 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Feb 2022, 3 months.
Results were first posted in Jul 2024, 2 years 5 months after primary completion.
Of 12 phase 1 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MYK-461
Cardiomyopathy, Hypertrophic →
LianBio LLC